JP2019512482A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512482A5
JP2019512482A5 JP2018546618A JP2018546618A JP2019512482A5 JP 2019512482 A5 JP2019512482 A5 JP 2019512482A5 JP 2018546618 A JP2018546618 A JP 2018546618A JP 2018546618 A JP2018546618 A JP 2018546618A JP 2019512482 A5 JP2019512482 A5 JP 2019512482A5
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
carboxamide
trifluoromethyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546618A
Other languages
English (en)
Japanese (ja)
Other versions
JP7624690B2 (ja
JP2019512482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2017/050269 external-priority patent/WO2017147700A1/en
Publication of JP2019512482A publication Critical patent/JP2019512482A/ja
Publication of JP2019512482A5 publication Critical patent/JP2019512482A5/ja
Priority to JP2022028700A priority Critical patent/JP2022071046A/ja
Priority to JP2024071190A priority patent/JP2024102151A/ja
Application granted granted Critical
Publication of JP7624690B2 publication Critical patent/JP7624690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546618A 2016-03-01 2017-03-01 Wdr5タンパク質-タンパク質結合の阻害剤 Active JP7624690B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022028700A JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤
JP2024071190A JP2024102151A (ja) 2016-03-01 2024-04-25 Wdr5タンパク質-タンパク質結合の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301673P 2016-03-01 2016-03-01
US62/301,673 2016-03-01
PCT/CA2017/050269 WO2017147700A1 (en) 2016-03-01 2017-03-01 Inhibitors of wdr5 protein-protein binding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022028700A Division JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤

Publications (3)

Publication Number Publication Date
JP2019512482A JP2019512482A (ja) 2019-05-16
JP2019512482A5 true JP2019512482A5 (enExample) 2020-04-09
JP7624690B2 JP7624690B2 (ja) 2025-01-31

Family

ID=59743306

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546618A Active JP7624690B2 (ja) 2016-03-01 2017-03-01 Wdr5タンパク質-タンパク質結合の阻害剤
JP2022028700A Pending JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤
JP2024071190A Pending JP2024102151A (ja) 2016-03-01 2024-04-25 Wdr5タンパク質-タンパク質結合の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022028700A Pending JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤
JP2024071190A Pending JP2024102151A (ja) 2016-03-01 2024-04-25 Wdr5タンパク質-タンパク質結合の阻害剤

Country Status (17)

Country Link
US (2) US11319299B2 (enExample)
EP (1) EP3423451B1 (enExample)
JP (3) JP7624690B2 (enExample)
KR (1) KR20180120720A (enExample)
CN (1) CN109195965B (enExample)
AU (1) AU2017226004B2 (enExample)
BR (1) BR112018067392A2 (enExample)
CA (1) CA3015406A1 (enExample)
CL (1) CL2018002505A1 (enExample)
CO (1) CO2018010504A2 (enExample)
DK (1) DK3423451T3 (enExample)
EA (1) EA038109B1 (enExample)
EC (1) ECSP18073726A (enExample)
IL (1) IL261472B (enExample)
MX (1) MX2018010374A (enExample)
WO (1) WO2017147700A1 (enExample)
ZA (1) ZA201805879B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019507179A (ja) 2016-03-01 2019-03-14 プロペロン セラピューティックス インコーポレイテッド Wdr5タンパク質−タンパク質結合の阻害剤
US11319299B2 (en) * 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ezh2-매개성 암 치료용 조성물 및 방법
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
KR102816969B1 (ko) 2017-03-27 2025-06-10 하이드로-퀘벡 전해질 조성물에서 또는 전극 첨가제로서 사용하기 위한 염
WO2019046944A1 (en) * 2017-09-06 2019-03-14 Propellon Therapeutics Inc. INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN
US10501466B2 (en) 2017-09-19 2019-12-10 Vanderbilt University WDR5 inhibitors and modulators
JP2021510152A (ja) * 2018-01-04 2021-04-15 北京大学深▲ヂェン▼研究生院Peking University Shenzhen Graduate School Lsd1とhdacとを標的として同時に阻害する化合物及びその用途
JP2021515013A (ja) 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
US10844044B2 (en) 2018-06-14 2020-11-24 Vanderbilt University WDR5 inhibitors and modulators
EP3810145A4 (en) * 2018-06-21 2022-06-01 Icahn School of Medicine at Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
US10807959B2 (en) 2018-08-16 2020-10-20 Vanderbilt University WDR5-MLL1 inhibitors and modulators
CN109734674B (zh) 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
JP7503851B2 (ja) 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Hpk1の分解剤としてのヘテロ二官能性化合物
CN111039860B (zh) * 2019-12-02 2022-09-13 河北科技大学 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用
CN113024538B (zh) * 2019-12-24 2022-09-09 南开大学 吡唑酰胺类化合物及其制备和在防治植物病菌病和杀虫中的应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN114539073A (zh) * 2022-02-18 2022-05-27 郑州萃智医药科技有限公司 3-溴-2-氯-4,6-二氟苯胺的合成方法
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc BLOOD-BRAIN BARRIER CROSSING PROTEIN-PROTEIN INTERACTION INHIBITORS (MLL1-WDR5) AND THEIR USES
US20230286948A1 (en) * 2022-03-14 2023-09-14 Huyabio International, Llc Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
CN119365449A (zh) * 2022-07-01 2025-01-24 甘李药业股份有限公司 一种用作wdr5抑制剂的化合物或其可药用盐及其应用
WO2024015478A2 (en) * 2022-07-14 2024-01-18 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
CN115974965B (zh) * 2022-08-31 2025-09-12 中国科学技术大学 一种靶向wdr5的多肽抑制剂及其用途
WO2026058961A1 (en) 2024-09-13 2026-03-19 Alivexis, Inc. Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用
CN119661474A (zh) * 2024-12-16 2025-03-21 中国药科大学 一类羟肟酸类的双靶点化合物衍生物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354309B1 (ko) 1993-11-12 2003-01-06 파마시아 앤드 업존 캄파니 피리미딘-티오알킬및알킬에테르화합물
JPH0959236A (ja) 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
US20010051719A1 (en) 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2-取代的4-杂芳基-嘧啶、其组合物及其用途
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CN1681487A (zh) 2002-07-15 2005-10-12 美瑞德生物工程公司 化合物、组合物及其使用方法
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
GB0412072D0 (en) 2004-05-28 2004-06-30 Syngenta Participations Ag Chemical compounds
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
WO2006081172A2 (en) 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
KR20080092412A (ko) 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
CA2644143C (en) 2006-04-05 2013-10-01 Novartis Ag Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
BRPI0813356A2 (pt) 2007-06-15 2014-12-30 Irm Llc Inibidores de proteína quinase e métodos para uso dos mesmos
CN101875617B (zh) 2009-03-23 2015-05-20 中国医学科学院药物研究所 烷氧基取代芳环的氨甲酰基类芳酸化合物及其制法和用途
MX2011011661A (es) 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
WO2011149874A2 (en) 2010-05-26 2011-12-01 Schering Corporation N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011156557A2 (en) 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
WO2011159685A2 (en) 2010-06-16 2011-12-22 The Regents Of The University Of Michigan Inhibition of wdr5 interaction with its binding partners and therapeutic methods
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
TW201406736A (zh) 2012-06-28 2014-02-16 Fujifilm Corp 新穎的醯胺衍生物或其鹽
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
CA2887598A1 (en) 2012-10-12 2014-04-17 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
US9079866B2 (en) 2013-02-04 2015-07-14 Janssen Pharmaceutica Nv Flap modulators
CA2932353A1 (en) 2013-12-13 2015-06-18 Steven P. Treon Methods to treat lymphoplasmacytic lymphoma
EP3079683A4 (en) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN104926801B (zh) * 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN105585565B (zh) 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
CN105175284B (zh) * 2015-07-21 2017-06-16 中国药科大学 酰胺类化合物、制备方法及其医药用途
JP2019507179A (ja) 2016-03-01 2019-03-14 プロペロン セラピューティックス インコーポレイテッド Wdr5タンパク質−タンパク質結合の阻害剤
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
US11319299B2 (en) 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
US10160763B2 (en) 2016-09-13 2018-12-25 Vanderbilt University WDR5 inhibitors and modulators
WO2019046944A1 (en) 2017-09-06 2019-03-14 Propellon Therapeutics Inc. INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN
US10501466B2 (en) 2017-09-19 2019-12-10 Vanderbilt University WDR5 inhibitors and modulators
WO2020086857A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Wdr5 inhibitors and modulators
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds

Similar Documents

Publication Publication Date Title
JP2019512482A5 (enExample)
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
JP2010510319A5 (enExample)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP4638355B2 (ja) チアゾール誘導体
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
JP2010533158A5 (enExample)
SI3083586T1 (en) The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products
JP2016523911A5 (enExample)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2014062093A5 (enExample)
JP2016517878A5 (enExample)
JP2019507179A5 (enExample)
IL303196B1 (en) Heteroaryl substituted pyridines and methods of use
JP2010513444A5 (enExample)
HRP20110520T1 (hr) Acilaminopirazoli kao inhibitori fgfr
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2016523976A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2017530999A5 (enExample)
ME01507B (me) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
JP2016534023A5 (enExample)
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы